Diligence memo · auto-generated · as of July 2, 2026
Exodos Life Sciences Limited Partnership
Exodos Life Sciences Limited Partnership looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Exodos Life Sciences Limited Partnership operates in Pharmaceuticals, based in Chapel Hill.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Exodos Life Sciences Limited Partnership has raised $2.7M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $1.0M on 2010-08-03.
Most recent recorded round closed around 2014-02-04.
Valuation (modeled)modeled
Provath models Exodos Life Sciences Limited Partnership at approximately $33M (range $385K–$369M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.87× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 12.4 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 2.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 32% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.